Groupama Asset Managment Sells 5,169 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Groupama Asset Managment lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 62,701 shares of the biopharmaceutical company’s stock after selling 5,169 shares during the quarter. Groupama Asset Managment owned about 0.06% of Regeneron Pharmaceuticals worth $35,255,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $226,000. Dorsey & Whitney Trust CO LLC boosted its position in shares of Regeneron Pharmaceuticals by 40.2% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 145 shares in the last quarter. Frank Rimerman Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.3% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 981 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 67 shares in the last quarter. Finally, Empowered Funds LLC grew its stake in shares of Regeneron Pharmaceuticals by 328.6% in the 2nd quarter. Empowered Funds LLC now owns 9,400 shares of the biopharmaceutical company’s stock valued at $4,935,000 after buying an additional 7,207 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $744.12 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The business has a 50-day simple moving average of $767.89 and a two-hundred day simple moving average of $698.50. The company has a market capitalization of $78.67 billion, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 2.04 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the business posted $12.07 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Evercore raised their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research note on Thursday, January 22nd. HSBC initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price objective for the company. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Finally, Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last 90 days. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.